新型疗法可完全治愈艾滋病!

2016-10-08 佚名 生物谷

(图片摘自www.sciencealert.com)英国最近的一项HIV治疗临床试验结果表明,在50名接受治疗的患者中,有一名患者其血液中第一次没有检测到任何的HIV病毒颗粒。这一结果十分令人高兴,但说到HIV的治愈还为时尚早。医生们怀疑HIV可能还会复发,而且由于患者体内存在大量的抗HIV药物,因此也无法证明HIV确实完全被清除了。来自英国的研究者们则认为他们的试验结果能够为HIV的治疗提供新的


(图片摘自www.sciencealert.com)

英国最近的一项HIV治疗临床试验结果表明,在50名接受治疗的患者中,有一名患者其血液中第一次没有检测到任何的HIV病毒颗粒。

这一结果十分令人高兴,但说到HIV的治愈还为时尚早。医生们怀疑HIV可能还会复发,而且由于患者体内存在大量的抗HIV药物,因此也无法证明HIV确实完全被清除了。

来自英国的研究者们则认为他们的试验结果能够为HIV的治疗提供新的思路。

"这是HIV完全治愈方向上的一步认真的尝试",研究者之一,来自NIH临床研究分支办公室的主任Mark Samuels说道。

"我们正在努力开发HIV的治愈方法,这一领域的研究十分困难,但我们也取得了不错的进展"。

HIV长久以来被认为是难以治疗的疾病,主要原因是该病毒能够潜藏在宿主的细胞内部,从而避免免疫系统的攻击。

这一新型的疗法首次寄希望于摧毁机体内部所有的HIV成分,它通过将特异性识别储藏有HIV的宿主细胞的药物以及一类疫苗成分结合起来,能够帮助免疫系统找到这些储藏库中的病毒并进行杀伤。

首先,研究者们给病人注射疫苗,从而唤醒体内的免疫系统,之后,他们将一类叫做Vorinostat的药物输入患者体内,从而将储藏有HIV的细胞也找到,便于免疫系统进行杀伤。

常规的抗逆转录病毒药物能够有效地组织HIV的复制,但难以完全消灭它们。但这一新型的疗法则被证明能够完全清楚体内的病毒成分。

这位被"治愈"的不知名患者是一位44岁的男性。治疗之后,通过目前的检测手段已经检测不到体内的任何病毒成分。在接下来的几个月中,随着抗逆转录病毒药物的逐渐弃用,我们能够更好地判断该病人是否真正得到了治愈。

到目前为止,唯一的一位被治愈的HIV患者是一名叫Timothy Ray Brown的美国人,他在接受骨髓移植手术之后,其体内的HIV也惊人的得到了清除。然而,由于这一疗法危险系数较大,而且十分昂贵,因此需要新型的替代疗法。

原始出处

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1924864, encodeId=50011924864af, content=<a href='/topic/show?id=7d1558259f5' target=_blank style='color:#2F92EE;'>#新型疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58259, encryptionId=7d1558259f5, topicName=新型疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Dec 05 12:09:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148606, encodeId=271f14860631, content=too young too simple, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73e1103049, createdName=kukuwawawa, createdTime=Sat Oct 15 13:46:40 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147731, encodeId=d9a614e731a9, content=文章真好,喜欢阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Oct 13 14:43:48 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147227, encodeId=00a314e22792, content=诺奖指日可待啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57ab1959292, createdName=boc_111, createdTime=Wed Oct 12 22:32:15 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145418, encodeId=8086145418b8, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 20:20:01 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145416, encodeId=3f7d1454161d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 20:19:55 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144307, encodeId=a7c214430e9d, content=好文章,长见识, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 14:53:41 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142864, encodeId=3038142864ef, content=希望人类早日攻克艾滋病, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=963a73788, createdName=molly12345, createdTime=Sun Oct 09 23:39:12 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1924864, encodeId=50011924864af, content=<a href='/topic/show?id=7d1558259f5' target=_blank style='color:#2F92EE;'>#新型疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58259, encryptionId=7d1558259f5, topicName=新型疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Dec 05 12:09:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148606, encodeId=271f14860631, content=too young too simple, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73e1103049, createdName=kukuwawawa, createdTime=Sat Oct 15 13:46:40 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147731, encodeId=d9a614e731a9, content=文章真好,喜欢阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Oct 13 14:43:48 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147227, encodeId=00a314e22792, content=诺奖指日可待啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57ab1959292, createdName=boc_111, createdTime=Wed Oct 12 22:32:15 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145418, encodeId=8086145418b8, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 20:20:01 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145416, encodeId=3f7d1454161d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 20:19:55 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144307, encodeId=a7c214430e9d, content=好文章,长见识, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 14:53:41 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142864, encodeId=3038142864ef, content=希望人类早日攻克艾滋病, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=963a73788, createdName=molly12345, createdTime=Sun Oct 09 23:39:12 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
    2016-10-15 kukuwawawa

    too young too simple

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1924864, encodeId=50011924864af, content=<a href='/topic/show?id=7d1558259f5' target=_blank style='color:#2F92EE;'>#新型疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58259, encryptionId=7d1558259f5, topicName=新型疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Dec 05 12:09:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148606, encodeId=271f14860631, content=too young too simple, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73e1103049, createdName=kukuwawawa, createdTime=Sat Oct 15 13:46:40 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147731, encodeId=d9a614e731a9, content=文章真好,喜欢阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Oct 13 14:43:48 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147227, encodeId=00a314e22792, content=诺奖指日可待啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57ab1959292, createdName=boc_111, createdTime=Wed Oct 12 22:32:15 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145418, encodeId=8086145418b8, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 20:20:01 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145416, encodeId=3f7d1454161d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 20:19:55 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144307, encodeId=a7c214430e9d, content=好文章,长见识, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 14:53:41 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142864, encodeId=3038142864ef, content=希望人类早日攻克艾滋病, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=963a73788, createdName=molly12345, createdTime=Sun Oct 09 23:39:12 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
    2016-10-13 1e10c84am36(暂无匿称)

    文章真好,喜欢阅读

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1924864, encodeId=50011924864af, content=<a href='/topic/show?id=7d1558259f5' target=_blank style='color:#2F92EE;'>#新型疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58259, encryptionId=7d1558259f5, topicName=新型疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Dec 05 12:09:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148606, encodeId=271f14860631, content=too young too simple, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73e1103049, createdName=kukuwawawa, createdTime=Sat Oct 15 13:46:40 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147731, encodeId=d9a614e731a9, content=文章真好,喜欢阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Oct 13 14:43:48 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147227, encodeId=00a314e22792, content=诺奖指日可待啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57ab1959292, createdName=boc_111, createdTime=Wed Oct 12 22:32:15 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145418, encodeId=8086145418b8, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 20:20:01 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145416, encodeId=3f7d1454161d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 20:19:55 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144307, encodeId=a7c214430e9d, content=好文章,长见识, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 14:53:41 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142864, encodeId=3038142864ef, content=希望人类早日攻克艾滋病, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=963a73788, createdName=molly12345, createdTime=Sun Oct 09 23:39:12 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
    2016-10-12 boc_111

    诺奖指日可待啊

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1924864, encodeId=50011924864af, content=<a href='/topic/show?id=7d1558259f5' target=_blank style='color:#2F92EE;'>#新型疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58259, encryptionId=7d1558259f5, topicName=新型疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Dec 05 12:09:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148606, encodeId=271f14860631, content=too young too simple, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73e1103049, createdName=kukuwawawa, createdTime=Sat Oct 15 13:46:40 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147731, encodeId=d9a614e731a9, content=文章真好,喜欢阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Oct 13 14:43:48 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147227, encodeId=00a314e22792, content=诺奖指日可待啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57ab1959292, createdName=boc_111, createdTime=Wed Oct 12 22:32:15 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145418, encodeId=8086145418b8, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 20:20:01 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145416, encodeId=3f7d1454161d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 20:19:55 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144307, encodeId=a7c214430e9d, content=好文章,长见识, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 14:53:41 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142864, encodeId=3038142864ef, content=希望人类早日攻克艾滋病, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=963a73788, createdName=molly12345, createdTime=Sun Oct 09 23:39:12 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
    2016-10-11 知难而进

    继续关注!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1924864, encodeId=50011924864af, content=<a href='/topic/show?id=7d1558259f5' target=_blank style='color:#2F92EE;'>#新型疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58259, encryptionId=7d1558259f5, topicName=新型疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Dec 05 12:09:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148606, encodeId=271f14860631, content=too young too simple, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73e1103049, createdName=kukuwawawa, createdTime=Sat Oct 15 13:46:40 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147731, encodeId=d9a614e731a9, content=文章真好,喜欢阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Oct 13 14:43:48 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147227, encodeId=00a314e22792, content=诺奖指日可待啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57ab1959292, createdName=boc_111, createdTime=Wed Oct 12 22:32:15 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145418, encodeId=8086145418b8, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 20:20:01 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145416, encodeId=3f7d1454161d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 20:19:55 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144307, encodeId=a7c214430e9d, content=好文章,长见识, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 14:53:41 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142864, encodeId=3038142864ef, content=希望人类早日攻克艾滋病, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=963a73788, createdName=molly12345, createdTime=Sun Oct 09 23:39:12 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
    2016-10-11 知难而进

    谢谢分享!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1924864, encodeId=50011924864af, content=<a href='/topic/show?id=7d1558259f5' target=_blank style='color:#2F92EE;'>#新型疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58259, encryptionId=7d1558259f5, topicName=新型疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Dec 05 12:09:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148606, encodeId=271f14860631, content=too young too simple, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73e1103049, createdName=kukuwawawa, createdTime=Sat Oct 15 13:46:40 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147731, encodeId=d9a614e731a9, content=文章真好,喜欢阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Oct 13 14:43:48 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147227, encodeId=00a314e22792, content=诺奖指日可待啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57ab1959292, createdName=boc_111, createdTime=Wed Oct 12 22:32:15 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145418, encodeId=8086145418b8, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 20:20:01 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145416, encodeId=3f7d1454161d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 20:19:55 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144307, encodeId=a7c214430e9d, content=好文章,长见识, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 14:53:41 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142864, encodeId=3038142864ef, content=希望人类早日攻克艾滋病, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=963a73788, createdName=molly12345, createdTime=Sun Oct 09 23:39:12 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
    2016-10-11 1e10c84am36(暂无匿称)

    好文章,长见识

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1924864, encodeId=50011924864af, content=<a href='/topic/show?id=7d1558259f5' target=_blank style='color:#2F92EE;'>#新型疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58259, encryptionId=7d1558259f5, topicName=新型疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Dec 05 12:09:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148606, encodeId=271f14860631, content=too young too simple, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73e1103049, createdName=kukuwawawa, createdTime=Sat Oct 15 13:46:40 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147731, encodeId=d9a614e731a9, content=文章真好,喜欢阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Oct 13 14:43:48 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147227, encodeId=00a314e22792, content=诺奖指日可待啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57ab1959292, createdName=boc_111, createdTime=Wed Oct 12 22:32:15 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145418, encodeId=8086145418b8, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 20:20:01 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145416, encodeId=3f7d1454161d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 20:19:55 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144307, encodeId=a7c214430e9d, content=好文章,长见识, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 14:53:41 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142864, encodeId=3038142864ef, content=希望人类早日攻克艾滋病, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=963a73788, createdName=molly12345, createdTime=Sun Oct 09 23:39:12 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
    2016-10-09 molly12345

    希望人类早日攻克艾滋病

    0

相关资讯

艾滋率高升,背后竟隐藏如此真相……

9月14日,江西省南昌市疾控中心发布通告称,自2005年首次报告青年学生艾滋病病例以来,至2016年8月底,南昌全市已有37所高校报告艾滋病(AIDS)感染者或病人,共报告存活学生HIV感染者和病人135例,死亡7例。同时,近年来南昌市青年学生HIV/AIDS病例快速增加,近5年疫情年增长率为43.16%;2011~2015年新发学生病例中,男男同性性传播占83.61%,同性性传播已成为青年学

原来很多疾病的名字起得这么轻率,太坑人了!

1932年,三名来自纽约的医生在美国医学协会杂志(JAMA)上发表了一篇论文,报道了一种新型肠道疾病。当时,这种肠道疾病就是以该论文第一作者Burrill B. Crohn的名字命名的。没成想,Burrill B.Crohn(克罗恩病是一种原因不明的肠道炎症性疾病,在胃肠道的任何部位均可发生,但好发于末端回肠和右半结肠)因此“名垂青史”,跟Alois Alzheimer(这位大兄弟,大家一定熟

吉利德HIV药物Truvada(特鲁瓦达)获英国NICE支持用于HIV暴露前预防治疗(PrEP)

美国生物技术巨头吉利德(Gilead)艾滋病管线近日在英国监管方面传来喜讯,英国国家卫生与临床优化研究所(NICE)已发布了一份有关HIV复方药Truvada用于感染高风险成人群体暴露前预防性治疗(PrEP)的证据总结。根据已获得的证据,Truvada在降低高危未感染成人群体中获得性HIV感染风险方面具有显著的临床疗效。此外,这份证据总结也表明,提供PrEP可能会增加其他健康服务的获取,例如艾

多篇文章深入解读中草药是否真的可以治疗多种疾病?(上)

中医药是我国的国粹和瑰宝,也是是开发治疗多种疾病新型疗法的“金矿”。据世界卫生组织统计,目前在全世界大约有40亿人在使用中草药治病,占世界总人口的80%,而且世卫组织推测,中草药的开发利用在未来的10年内将在世界上全面兴起。很多关于中草药治疗疾病的研究在我国非常之多,而在国外相关的研究进展却相对较少,国外科学家们一直对中药草的真实疗效报以怀疑态度,部分原因是他们认为中草药中所含的成分较多,较为

Nat Med:HIV“黄金”抗体因人而异的3大影响因素

广泛性中和抗体(bNAbs)是一种被证实能够有效防控多种HIV病毒变异的有效抗体,是应对艾滋病病毒扩增、突变的长效武器。它不仅仅能够直接靶向宿主体内的病毒毒株,还能够有效攻击全球流行的其他病毒变种。这一类抗体被认为是艾滋病疫苗的关键成分,备受科学家们关注。但是,已有数据却揭示,只有很少一部分HIV感染者体内会生成广泛性中和抗体,且表达时间通常需要数年时间,甚至于数十年!这远远失去了免疫的意义。那么

首例成功治癒的爱滋患者?英男体内HIV病毒完全消失

导语:爱滋病治疗出现极大进展。人类头号传染病爱滋病(后天免疫缺乏症候群,AIDS)的治疗研究出现重大进展。由英国5所顶尖大学组成的研究团队,研发出一项以根治爱滋病为目标的治疗技术,消灭爱滋患者体内所有感染病毒的细胞,而一名患者近日在接受治疗后,出现痊癒迹象。据《BBC》及《泰唔士报》报导,这项英国全民健保所发起的研究计画,由牛津大学、剑桥大学、帝国理工大学、伦敦大学学院和国王学院携手进行。有50位